Thiogenesis Therapeutics, Corp.
TTIPF
$0.42
-$0.03-6.67%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.96% | -2.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -46.84% | -28.58% | |||
| Operating Income | 46.84% | 28.58% | |||
| Income Before Tax | 47.22% | 28.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.22% | 28.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.22% | 28.23% | |||
| EBIT | 46.84% | 28.58% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 47.28% | 30.92% | |||
| Normalized Basic EPS | 47.33% | 30.56% | |||
| EPS Diluted | 47.28% | 30.92% | |||
| Normalized Diluted EPS | 47.33% | 30.56% | |||
| Average Basic Shares Outstanding | -0.07% | 3.55% | |||
| Average Diluted Shares Outstanding | -0.07% | 3.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||